60 Degrees Pharmaceuticals (SXTP) Current Assets (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Current Assets of $6.3 million for Q1 2026, up 10.8% year-over-year from $5.7 million in Q1 2025, and up 27.88% quarter-over-quarter from $4.9 million in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Current Assets (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Current Assets for 5 consecutive years, with $6.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 10.8% year-over-year to $6.3 million; the TTM figure through Mar 2026 stood at $6.3 million (up 10.8% YoY), while the FY2025 annual figure was $4.9 million, down 9.11% from the prior year.
- Current Assets advanced to $6.3 million in Q1 2026 per SXTP's latest filing, from $4.9 million in the prior quarter.
- Across five years, Current Assets topped out at $8.9 million in Q3 2023 and bottomed at $1.1 million in Q4 2022.
- Historically, Current Assets has averaged $5.7 million across 5 years, with a median of $5.7 million in 2023.
- Annual changes were most pronounced in 2023 — Current Assets soared 559.01% — and 2024, when it sank 33.69%.
- 60 Degrees Pharmaceuticals' Current Assets stood at $1.1 million in 2022, then jumped by 559.01% to $7.2 million in 2023, then dropped by 25.63% to $5.4 million in 2024, then dropped by 9.11% to $4.9 million in 2025, then rose by 27.88% to $6.3 million in 2026.
- Business Quant data shows SXTP's Current Assets at $6.3 million in Q1 2026, $4.9 million in Q4 2025, and $6.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.56 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.72 Bn | 60.53 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.75 Bn | 53.61 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.59 Bn | 10.19 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.63 Bn | 26.47 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.24 Bn | 26.40 Bn | - | 1.76 Bn |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 | 3.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.26 Mn |
| Dec 31, 2025 | 4.90 Mn |
| Sep 30, 2025 | 6.31 Mn |
| Jun 30, 2025 | 3.84 Mn |
| Mar 31, 2025 | 5.65 Mn |
| Dec 31, 2024 | 5.39 Mn |
| Sep 30, 2024 | 6.89 Mn |
| Jun 30, 2024 | 3.76 Mn |
| Mar 31, 2024 | 7.91 Mn |
| Dec 31, 2023 | 7.24 Mn |
| Sep 30, 2023 | 8.89 Mn |
| Jun 30, 2023 | 5.67 Mn |
| Dec 31, 2022 | 1.10 Mn |